GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (XBRU:UCB) » Definitions » Cyclically Adjusted Price-to-FCF

UCB (XBRU:UCB) Cyclically Adjusted Price-to-FCF : 23.18 (As of Apr. 30, 2024)


View and export this data going back to 1988. Start your Free Trial

What is UCB Cyclically Adjusted Price-to-FCF?

As of today (2024-04-30), UCB's current share price is €123.55. UCB's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 was €5.33. UCB's Cyclically Adjusted Price-to-FCF for today is 23.18.

The historical rank and industry rank for UCB's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

XBRU:UCB' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 13.26   Med: 23.2   Max: 35.12
Current: 23.38

During the past 13 years, UCB's highest Cyclically Adjusted Price-to-FCF was 35.12. The lowest was 13.26. And the median was 23.20.

XBRU:UCB's Cyclically Adjusted Price-to-FCF is ranked better than
80.39% of 102 companies
in the Biotechnology industry
Industry Median: 54.05 vs XBRU:UCB: 23.38

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

UCB's adjusted free cash flow per share data of for the fiscal year that ended in Dec23 was €2.280. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €5.33 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


UCB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for UCB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Cyclically Adjusted Price-to-FCF Chart

UCB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.18 22.52 23.24 14.84 14.81

UCB Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.24 - 14.84 - 14.81

Competitive Comparison of UCB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, UCB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UCB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UCB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where UCB's Cyclically Adjusted Price-to-FCF falls into.



UCB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

UCB's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=123.55/5.33
=23.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, UCB's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=2.28/128.2922*128.2922
=2.280

Current CPI (Dec23) = 128.2922.

UCB Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 4.106 99.086 5.316
201512 1.041 100.572 1.328
201612 3.068 102.614 3.836
201712 7.627 104.804 9.336
201812 7.937 107.252 9.494
201912 6.095 108.065 7.236
202012 3.768 108.511 4.455
202112 5.459 114.705 6.106
202212 3.839 126.578 3.891
202312 2.280 128.292 2.280

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


UCB  (XBRU:UCB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


UCB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of UCB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


UCB (XBRU:UCB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (XBRU:UCB) » Definitions » Cyclically Adjusted Price-to-FCF
Address
Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (XBRU:UCB) Headlines

No Headlines